Last reviewed · How we verify

NCT05420610

Early Goal-Directed Therapy Utilizing Transpulmonary Thermodilution and Severe Burn Injury

Completed Last updated 15 June 2022
What this trial tests

trial testing Control group: Patients being admitted when The advancement of transpulmonary thermodilution(TPTD) device was unavailable. in Burns in 66 participants. Completed in 20 January 2022.

Timeline
7 August 2021
Primary endpoint
30 November 2021
20 January 2022

Quick facts

Lead sponsorChang Gung Memorial Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment66
Start date7 August 2021
Primary completion30 November 2021
Estimated completion20 January 2022
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 18 to 100, any sex, with Burns. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to optimize fluid resuscitation with transpulmonary thermodilution (TPTD)-guided protocol and to lower the mortality rate of the severely burned.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Burns

Currently open trials in the same condition.

Other Chang Gung Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05420610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing